BioSpace News Archive

MediciNova, Inc., today announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine (2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan) to evaluate the mechanism of the action of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome.

Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.

Biocartis Group NV announced that it has entered into an agreement with AstraZeneca aimed at the development and applicable pre-market notification or approval with the US FDA of a novel companion diagnostic1 test on Biocartis’ molecular rapid and easy-to-use diagnostics Idylla™ platform, for use with Tagrisso®, AstraZeneca’s third-generation EGFR-TKI treatment.

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that the Company has secured an additional contract with its first large-scale pharma services customer.

Body fat measurement is swiftly becoming a highly sought-after medical diagnostics and lifestyle self-inspection.

Wilmington, Delaware, United States: Mesotherapy is a technique that is used to inject vitamins, enzymes, hormones, and plant extracts to rejuvenate and tighten skin as well as remove excess fat.

LumiThera Inc announced detailed findings in its LIGHTSITE III, multi-center clinical trial in non-neovascular Age-Related Macular Degeneration subjects treated with Photobiomodulation using the Valeda® Light Delivery System.

Echosens and Novo Nordisk A/S announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis and increase awareness of the disease among patients, healthcare providers and other stakeholders.

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of a research test, codeveloped with Merck.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) to include children 6 weeks through 17 years of age.